Bone marrow cancer drug shows success in treatment of rare blood disorder
September 18, 2024
September 18, 2024
WASHINGTON, Sept. 18 -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release:
NIH-supported clinical trial is the first positive trial for treatment of hereditary hemorrhagic telangiectasia.
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug used to treat bone marrow cancer and Kaposi sarcoma is safe and effective in t . . .
NIH-supported clinical trial is the first positive trial for treatment of hereditary hemorrhagic telangiectasia.
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug used to treat bone marrow cancer and Kaposi sarcoma is safe and effective in t . . .